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background: Essential thrombocytosis (ET) is a myeloproliferative disorder characterized by thrombocythemia that has both hemorrhagic and 
thrombotic manifestation. The incidence of Acute Coronary Syndrome (ACS) as a thrombotic manifestation of ET is 10-20%.
case: 64-year-old man with medical history of hypertension and tobacco use presented with syncope after lightheadedness and blurry vision. He 
regained consciousness without neurological deficits. He denied any other cardiovascular symptoms. In the emergency room, he had an episode 
of aphasia and left sided sensory deficit with complete resolution in few minutes. Physical examination was unremarkable. CT brain was negative 
for bleed. EKG was initially unremarkable but later revealed progressive T Wave inversion in lateral leads. Troponin peaked at 9. Platelet count was 
908,000. CT of chest and abdomen showed possible thrombus in the abdominal aorta and hypodense areas in spleen. MRI of brain demonstrated 
multiple acute nonhemorrhagic infarcts involving several areas consistent with embolic stroke. JAK2 V617F mutation was positive.
Decision-making:  Our patient was diagnosed with NSTEMI and was treated with aspirin, plavix, enoxaparin, and eptifibatide. Although patient had 
cardiovascular risk factors, his high platelet count raised the possibility of ET especially when combined with other concurrent thrombotic events. 
Many theories were postulated for the cause of transient coronary occlusion from thrombocytosis such as selective lipoxygenase deficiency, altered 
platelet granule glycoprotein, increased activity of fibrinolysis inhibitors or increased thrombocyte procoagulant activity. Possibility of abdominal 
aortic thrombus prohibited coronary angiography. A regadenoson myoview study was normal. These suggested that his NSTEMI was from transient 
thrombosis secondary to ET. He was considered to be high risk for future thrombosis and was started on anagrelide for cytoreductive therapy.
conclusions: ET can be a cause of ACS with a different pathophysiology from atherosclerotic disease. This leads to an alteration of management in 
the long term. So far there are no guidelines for treatment of ACS in ET patient.
